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Background: Little is known about the relative contribution of comorbidities in predicting the 
health-related quality of life (HRQoL) of people with Multiple Sclerosis (PwMS).  
Objective: To determine the associations between the number of and individual comorbidities 
and HRQoL and estimate the relative contribution of different comorbidities on HRQoL. 
Methods: Cross-sectional analysis of data on self-reported presence of 30 comorbidities and 
HRQoL from the Australian MS Longitudinal Study (AMSLS) participants(n=902). HRQoL 
was measured using the Assessment of Quality of Life-8 Dimensions (AQoL-8D). Linear 
regression and general dominance analysis were used. 
Results: Higher number of comorbidities was associated with lower HRQoL (p-trend p<0.01). 
Comorbidities accounted for 18.1% of the variance in HRQoL. Mental health and 
musculoskeletal disorders were the strongest contributors to lower HRQoL. Of individual 
comorbidities, systemic lupus erythematosus (SLE) (β=-0.16(-0.27,-0.05)) and depression (β=-
0.15(-0.18,-0.13)) were most strongly associated with overall HRQoL, depression (β=-0.14(-
0.16,-0.11)) and anxiety (β=-0.10(-0.13,-0.07)) with psychosocial HRQoL, and SLE (β=-0.18(-
0.29,-0.07)),  rheumatoid arthritis (β=-0.11(-0.19,-0.02)) and hyperthyroidism (β=-0.11(-0.19,-
0.03)) with physical HRQoL.  
Conclusions: Comorbidities potentially make important contributions to HRQoL in PwMS. 
Our findings highlight groups of and individual comorbidities that could provide the largest 









One facet of Multiple Sclerosis (MS) management that has garnered significant research 
interest is enhancing the overall health-related quality of life (HRQoL) of people with MS 
(PwMS). HRQoL is a subjective concept capturing overall well-being and is defined by the 
World Health Organization as the“individual’s perception of their position in life in the context 
of the culture and value systems in which they live and in relation to their goals, expectations, 
standards and concerns”.1 Specifically, the MS International Federation describes the HRQoL 
of PwMS as multifaceted, highly interchangeable but very personal and influenced by many 
factors such as the environment, and various social circumstances.2 In MS, previous studies 
have already identified that age, sex, socio-economic status, disability progression, symptoms 
and other disease features can lower the HRQoL of PwMS.3-6 
PwMS are more likely to acquire comorbidities and have a lower HRQoL compared to the 
general population and to those with other chronic conditions.7, 8 Identifying the groups of or 
individual comorbidities that are associated with the largest reductions in HRQoL of PwMS 
could influence the recommendations around comorbidity screening and management. 
However, knowledge on the relative contribution of comorbidities as predictors of HRQoL in 
MS is very limited. Most studies have focussed on the total burden of comorbidities or only 
examined the associations between a small number of individual comorbidities and physical or 
mental HRQoL.4, 5, 7, 9-11 No studies have investigated the relative contribution of comorbidities 
to the HRQoL of PwMS.   
Using the comorbidity data of the Australian MS Longitudinal Study (AMSLS) participants, 
we aimed to (a) examine associations between the number of comorbidities and HRQoL; (b) 
estimate the relative contribution of groups of comorbidities in predicting HRQoL and; (c) 
determine the magnitude of the effects of individual comorbidities on HRQoL.  






The AMSLS is a large sample of around 3,000 adult Australian volunteers with MS.12 An 
estimated 96% of the participants were diagnosed by a neurologist with definite MS using the 
McDonald Criteria.13, 14 It is an ongoing survey-based research project supported by MS 
societies in all Australian states and territories. Ethical approval was initially given by the 
Australian Capital Territory Health Human Research Ethics Committee (HREC) and by the 
Tasmanian Health and Medical HREC when the study centre was relocated to Tasmania in 
2014.12   All participants provided informed consent. 
In 2016, active AMSLS participants were invited to complete 3 surveys. To assess 
comorbidities, we used the Lifestyle and Environment Survey ((August-October 2016); 3,112 
invitations sent; 1,518 (49%; 1,067 online and 451 paper) responded). To obtain clinical 
information, we used the Medication and Disease Course Survey ((November 2016-March 
2017); 3,098 invitations sent; 1,699 (55%; 1,282 online and 417 paper) responded). To assess 
HRQoL, we used the Economic Impact Baseline Survey ((March-May 2016); 3,163 invitations 
sent; 1,577 (50%; 1,112 online and 465 paper) responded). We included those who completed 




The participants were asked about the presence of 30 comorbidities that were frequently 
reported in prior comorbidity studies in MS.15-17 For each comorbidity, we asked “Do you have 
or have you had this condition?” (Yes/No). If yes, the participant was coded as having that 
comorbidity. We subsequently asked “Was it diagnosed by a doctor?” (Yes/No/Don’t know). 
If yes, the participant was coded as having that doctor-diagnosed comorbidity. The “Don’t 




know” group was combined with the “No” group.  The total comorbidities (i.e. any comorbidity 
the patient reported having) and doctor-diagnosed comorbidities (i.e. any comorbidity the 
patient reported as diagnosed by a doctor) were counted. The comorbidities were grouped 
according to the 263 blocks (disease categories) in the International Classification of Diseases–
10th revision (ICD-10) structure. Because of power considerations, only those comorbidities 
reported by at least 10 participants were assessed for their influence on HRQoL which excluded 
Parkinson’s disease, bipolar disorder and schizophrenia. The complete list of the 27 included 




We assessed HRQoL using the Assessment of Quality of Life-8 Dimensions (AQoL-8D) 
questionnaire, a comprehensive HRQoL instrument that describes billions of health states (2.4 
x 1023) and has 35 items with 2 super-dimensions and 8 domains (psychosocial super-
dimension (domains of happiness, coping, relationships, self-worth, and mental health) and 
physical super-dimension (domains of independent living, senses and pain)).18 The AQoL-8D 
has been validated for use for people with complex and chronic conditions like MS and only 
takes around 5 minutes to complete.19, 20 Scores range from 0 (death/worst health state) to 1 
(perfect health).  
 
Other measures 
MS duration was calculated by subtracting years since MS diagnosis from the survey date. 
Body mass index (BMI) was calculated by dividing self-reported weight (in kilograms) by 
height2 (in centimetres).  Data on sex, disease modifying therapy status, MS onset-type (i.e. 




relapse-onset and progressive-onset) and education attainment were also obtained from the 
2016 Medication and Disease Course Survey.  
 
Statistical analysis 
We used descriptive statistics to summarize participant characteristics. To ascertain the 
generalisability across the sample, we compared the characteristics of the included vs not-
included participants by performing student t-test and χ2 test. Associations between the number 
of comorbidities and AQoL-8D was evaluated using linear regression. A dose-response was 
assessed using a test-for-trend. We then performed a multivariable regression analysis by 
including all the comorbidity groups as predictor variables in the model and determined the 
association of each comorbidity groups on the overall AQoL-8D. Since a certain degree of 
correlation exists between the predictors in the model, we carried out general dominance 
analysis (domin package in Stata) to determine the relative contribution (%) each of the 
predictors made to the overall AQoL-8D.21, 22 Dominance analysis provides an intuitive 
measure of predictor importance in two ways: 1) it uses the change in model fit (i.e., R2) to 
determine the contribution of each predictor, and 2) it compares predictor contributions across 
all possible subset models from a given set of predictors.23, 24 Results were presented as general 
dominance weights, standardized to be out of 100%, to provide a ranking and weighting for 
each predictor in the model.23 We further examined the association of individual comorbidities 
and overall AQoL-8D by linear regression. We used those with no comorbidity as the reference 
group. Potential confounders were identified by using causal diagrams and by examining 
whether the coefficient of each outcome (i.e. AQoL-8D) variable was altered by more than 
10% when a covariate (i.e. age, sex, MS duration, MS onset-type (relapse-onset vs. 
progressive-onset) and education attainment) was added to the model.25, 26 We repeated all the 
analyses above for AQoL-8D’s physical and psychosocial super-dimensions. We performed 




sensitivity analyses by limiting to doctor-diagnosed comorbidities. For musculoskeletal 
disorders, we were concerned that the impact was driven by the systemic component of 
rheumatoid arthritis and SLE. We therefore repeated the analysis excluding these 
comorbidities. We performed regression diagnostics and examined residual errors for all 
models, but no transformations were needed. All analyses were performed using STATA/IC 
for Windows (version 15.0; StataCorp LP, College Station, Texas, USA).  
 
Results 
Prevalence of comorbidities 
Of the total cohort, 91.1% (n=817) of participants had > one comorbidity. The most prevalent 
mental health comorbidities were depression (41.2%) and anxiety (38.1%) (Table 1). Common 
physical comorbidities included allergies (37.4%), hypertension (29.9%), migraine (26.9%), 
high cholesterol (24.1%), osteoarthritis (22.2%), eye diseases (15.0%), cancer (14.6%) and 
osteoporosis (13.8%) (Table 1).  
Participant characteristics 
Participants were predominantly female (78.6%) and had a mean age of 55.8 years (Table 2). 
The average MS duration since diagnosis was 15.4 years, most had relapse-onset MS (87.4%), 
62.6% were currently receiving disease modifying therapy and 42.2% had normal BMI (as 
defined by BMI=18.5 to 25.0).  
The participants included in this analysis had a similar sex distribution (78.6% females vs. 
78.7%, p = 0.95) to participants who were not included. Included participants were slightly 
older (+1.80 years, p<0.01), had longer MS duration (+1.20 years p<0.01) and higher education 
attainment (39% with university degree or higher vs 33%, p=0.01).  




Association between the number of comorbidities and AQoL-8D 
A higher number of comorbidities was associated with lower overall AQoL-8D and AQoL-
8D’s physical and psychosocial super-dimensions with a clear dose-response relationship 
(Table 3), which persisted after adjusting for age, sex and education attainment.  We found no 
significant interactions between number of comorbidities and MS onset-type or sex for both 
total and doctor-diagnosed comorbidities (data not shown).  
Relative contribution of comorbidity groups to overall AQoL-8D 
All the comorbidity groups (n=13) accounted for 18.1% of the variance in the overall AQoL-
8D variable (Figure 1). Using general dominance analysis, we identified that 68.3% of this 
variance was contributed by mental health disorders followed by musculoskeletal disorders 
(12.6%). When rheumatoid arthritis and SLE were excluded from the musculoskeletal disorder 
group, the contribution of this group reduced from 12.6% to 10.8%. When we limited our 
analysis to doctor-diagnosed comorbidities, similar findings were observed (61.5% of the total 
14.7% variance in overall AQoL-8D was contributed by mental health disorders; 12.7% by 
musculoskeletal disorders) (Supplementary Figure 1). 
Relative contribution of comorbidity groups to AQoL-8D’s physical and psychosocial super-
dimensions 
The 13 comorbidity groups together accounted for 17.5% of the variance of the AQoL-8D’s 
psychosocial super-dimension and 12.7% of the variance in AQoL-8D’s physical super-
dimension (Figure 1). Mental health disorders contributed 80.9% and 19.7% of the AQoL-8D’s 
psychosocial and physical super-dimensions total variance respectively, making this group the 
strongest contributor of psychosocial HRQoL and the second most important contributor of 
physical HRQoL. Musculoskeletal disorders contributed 5.5% and 38.9% of the total AQoL-
8D’s psychosocial and physical super-dimensions variance, respectively. This comorbidity 




group is the second most important contributor to psychosocial HRQoL and the most important 
contributor to physical HRQoL. Similar patterns were seen with doctor-diagnosed 
comorbidities (Supplemental Figure 1). 
Association between individual comorbidities and overall AQoL-8D 
The mean overall AQoL-8D for PwMS with no reported comorbidities was 0.74 (95% CI: 0.69, 
0.78) after adjusting for age, sex and education attainment (Table 4). The comorbidities with 
an effect size greater than the recognised minimum important difference for the AQoL-8D   
(defined as β>0.08)19 were systemic lupus erythematosus (SLE) (β=-0.16), depression (β=-
0.15), hyperthyroidism (β=-0.12), anxiety (β=-0.11), inflammatory bowel disease (IBD) (β=-
0.10), rheumatoid arthritis (β=-0.09), osteoporosis and type 2 diabetes (β=-0.08). Other 
autoimmune diseases, heart diseases, osteoarthritis, migraine and allergies were also 
significantly associated with a lower AQoL-8D but the effect sizes were lower (β from -0.03 
to -0.07). The effect sizes for doctor-diagnosed comorbidities were similar (Supplementary 
Table 1).   
Association between individual comorbidities and AQoL-8D’s physical and psychosocial 
super-dimensions 
The mean AQoL-8D’s psychosocial super-dimension for PwMS with no reported 
comorbidities was 0.45 (95% CI: 0.41,0.49) and their mean AQoL-8D’s physical super-
dimension was 0.68 (95% CI: 0.64,0.72) after adjusting for age, sex and education attainment 
(Table 5). The comorbidities that were significantly associated with AQoL-8D’s psychosocial 
super-dimension with β>0.08 were depression (β=-0.14), anxiety (β=-0.10), hyperthyroidism 
(β=-0.09) and IBD (β=-0.08). SLE had an effect size of β=-0.09 but the association was not 
statistically significant. The effect sizes for doctor-diagnosed comorbidities were similar, 
although the effect size of IBD was lower and not significant ((β=-0.07) (Supplementary Table 




2). The comorbidities that were significantly associated with AQoL-8D’s physical super-
dimension with β>0.08 were SLE (β=-0.18), rheumatoid arthritis, hyperthyroidism (β=-0.11), 
depression, IBD and other autoimmune diseases (β=-0.10). Epilepsy and type 1 diabetes had 
effect sizes of β=-0.11 and β=-0.08, respectively and but the associations were not statistically 
significant. Again, the effect sizes for the doctor-diagnosed comorbidities were similar 
(Supplementary Table 2).   
 
Discussion 
This study, to the best of our knowledge, is the first to use a more superior and sensitive HRQoL 
instrument (i.e. AQoL-8D) to assess the relative contribution of different comorbidities 
grouped into ICD-10 categories and to estimate the magnitude of effects of a wide range of 
individual comorbidities on HRQoL. In this large population-based study of PwMS, the 
number of comorbidities was strongly associated with lower AQoL-8D in a dose-dependent 
fashion and comorbidities explained 18.1% of the variance of AQoL-8D score. Of all 
comorbidity groups, mental health disorders contributed most to overall AQoL-8D (68.1% of 
the overall comorbidity effect), with an even higher contribution seen for AQoL-8D’s 
psychosocial super-dimension (80.9%). Musculoskeletal disorders (38.9%) contributed most 
to AQoL-8D’s physical super-dimension. Of the individual comorbidities, the magnitude of 
effects on overall AQoL-8D were largest for SLE, depression, hyperthyroidism, anxiety, IBD, 
rheumatoid arthritis, osteoporosis and type 2 diabetes. These findings suggest that prevention 
and management of these comorbidities has the greatest potential to have an important impact 
on the HRQoL of PwMS. 




PwMS who did not report any comorbidity had a mean overall AQoL-8D of 0.73 which is 
considerably lower than the previously reported overall AQoL-8D of the general Australian 
population (~0.80).27 Those with 2 or 3 comorbidities had a mean overall AQoL-8D of 0.65 
while those with 4 or more comorbidities had a mean of 0.55, which is 0.08 and 0.18 units 
lower than those without comorbidities, and likely to be clinically important. Our observed 
association aligns with other studies.4, 7, 9 Given the high proportions of PwMS reporting 
comorbidities (~90% ≥1 comorbidity, ~36% with 2-3 comorbidities, and ~41% with ≥4 
comorbidities), there is therefore potential for a major gain in HRQoL through the prevention 
and optimal management of comorbidities.  
The comorbidity groups combined explained 18.1% of the variance of overall AQoL-8D, 
17.5% of AQoL-8D’s psychosocial super-dimension and 12.7% of AQoL-8D’s physical super-
dimension. Of that variance explained, our results highlighted that mental health disorders 
(including depression and anxiety) were by far the largest contributor to the overall (68.3%) 
and psychosocial super-dimension (80.9%) of AQoL-8D. Musculoskeletal disorders (i.e. 
osteoporosis, osteoarthritis, rheumatoid arthritis and SLE) were the largest contributors to the 
AQoL-8D’s physical super-dimension (38.9%) and were the second largest contributor to 
overall AQoL-8D (12.6%). Other comorbidity groups only had a relatively minor contribution 
in predicting the HRQoL of PwMS. Our findings were similar irrespective of whether we used 
the total or doctor-diagnosed comorbidities. Interestingly, a companion paper in this issue 
shows that mental health and musculoskeletal disorders were also the strongest contributors to 
the severity of the most common symptoms in MS.28 Collectively, our results emphasize the 
importance of early and routine screening of mental health and musculoskeletal disorders in 
achieving a better HRQoL in PwMS. 
The large contribution of mental health disorders to HRQoL in our study highlights the 
importance of these disorders in MS. For the individual mental health disorders, people with 




depression had an overall AQoL-8D reduction of 0.15 units, and those with anxiety a reduction 
of 0.11 units, with similar magnitude of effects were seen for AQoL-8D’s psychosocial super-
dimension and smaller but still potentially important effects on AQoL-8D’s physical super-
dimension. The results in our study are similar to a large effect size for depression and moderate 
effect size for anxiety on mental HRQoL of PwMS found by Berrigan et.al.9 These large effect 
sizes together with depression and anxiety having the highest prevalence of all comorbidities 
(33.6% reported as doctor-diagnosed depression, 20.2% reported as doctor-diagnosed anxiety) 
suggests that the population as well as the individual level impact of these comorbidities is 
substantial. We acknowledge that depression and anxiety could be the result of having MS or 
they could occur independently. In either case, our findings strongly support the notion that 
prompt and continuous screening during the disease course for these comorbidities should be 
conducted in PwMS,29-31 and that appropriate support and treatment should be pursued in order 
to minimise their impact.  
Musculoskeletal disorders contributed the most to the variance in AQoL-8D’s physical super-
dimension, whether we used total or doctor-diagnosed comorbidities. SLE was most strongly 
associated with a lower AQoL-8D’s physical super-dimension (-0.16) followed by rheumatoid 
arthritis (-0.09) although the prevalence of these comorbidities was relatively low. The impact 
of this comorbidity group remained the same when the analysis was limited to those with 
osteoporosis and osteoarthritis, suggesting the impact is largely driven by the physical 
disabilities rather than systemic effects associated with SLE and rheumatoid arthritis. Overall, 
musculoskeletal disorders are considered a major cause of physical disability and a significant 
contributor to pain.32 The pain and the physical limitations brought by these comorbidities also 
affect the AQoL-8D’s psychosocial super-dimension. Similar to our results, Woolf and Pfleger 
found that rheumatoid arthritis was more disabling than osteoarthritis or osteoporosis and was 
associated with a shorter life expectancy and even lower HRQoL particularly for those with 




severe forms of the disease.32 Osteoporosis contributed to a much lower HRQoL by 
substantially increasing long-term physical disability while the pain and disability experienced 
by those with osteoarthritis may lead to deterioration of health and wellbeing leading to a lower 
HRQoL of PwMS.33 Overall, recognising the large impact, instituting a timely intervention and 
developing preventative strategies to mitigate the occurrence or slow the progression of these 
comorbidities may result in a substantial improvement of HRQoL of PwMS.  
A major strength of this study is the inclusion of broad range of comorbidities, which also 
allowed us to group comorbidities and identify the relative contribution of these comorbidity 
groups on HRQoL. The study limitations should also be recognized.  The cross-sectional nature 
of our study precludes us from establishing causality between MS, comorbidities and HRQoL. 
Although the AMSLS is a highly representative sample of the MS population,12 some selection 
bias may have occurred as not all participants answered all 3 surveys. However, when we 
compared those who were included with those who were not included, differences in age, MS 
duration and education attainment were small. Further, our study sample is similar in sex and 
MS onset-types compared with other MS cohort studies,34 making our results likely 
generalisable to the whole MS population. Despite our large sample size, we had to exclude 
rare comorbidities due to power considerations. The comorbidities were self-reported, which 
might have caused some measurement error. To minimise this, we also asked whether the 
comorbidities were doctor-diagnosed. We found similar results for total and doctor-diagnosed 
comorbidities.   
In conclusion, comorbidities have a major impact of HRQoL in people with MS. By examining 
comorbidity groups and individual comorbidities our results specifically highlighted that 
mental health and musculoskeletal disorders have a substantial impact on HRQoL and should 
be targeted for early detection, prevention and optimal treatment in PwMS.  
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Table 1.  The prevalence of total and doctor-diagnosed comorbidities of the AMSLSa 







Mental health disorders   
      Depression 372 (41.2) 303 (33.6) 
      Anxiety 344 (38.1) 197 (21.8) 
Musculoskeletal disorders   
      Osteoporosis 124 (13.8) 119 (13.2) 
      Osteoarthritis 200 (22.2) 182 (20.2) 
      Rheumatoid arthritis 22 (2.4) 18 (2.0) 
      Systemic lupus erythematosus 14 (1.6) 13 (1.4) 
Endocrine and Metabolic diseases   
      High cholesterol 217 (24.1) 214 (23.7) 
      Type 1 diabetes 11 (1.2) 11 (1.2) 
      Type 2 diabetes 47 (5.2) 46 (5.1) 
      Hyperthyroidism 27 (3.0) 26 (2.9) 
      Hypothyroidism 72 (8.0) 70 (7.8) 
Diseases of the nervous system   
      Epilepsy 12 (1.3) 8 (0.9) 
      Migraine 243 (26.9) 152 (16.9) 
Diseases of the circulatory system   
      Hypertension 270 (29.9) 268 (29.7) 
      Heart diseases 59 (6.5) 57 (6.3) 
      Myocardial infarction 17 (1.9) 16 (1.8) 
      Stroke 22 (2.4) 21 (2.3) 
      Peripheral vascular disease 24 (2.7) 24 (2.7) 
Diseases of the digestive system   
      Inflammatory bowel disease 26 (2.9) 25 (2.8) 
      Coeliac disease 13 (1.4) 10 (1.1) 
Eye diseases 135 (15.0) 125 (13.9) 
Allergies 337 (37.4) 257 (28.5) 
Other autoimmune diseases 38 (4.2) 35 (3.9) 
Diseases of the skin   
       Psoriasis 78 (8.7) 61 (6.8) 
Diseases of the blood   
       Anaemia 108 (12.0) 103 (11.4) 
Neoplasms   
       Cancer 132 (14.6) 130 (14.4) 
Diseases of the genito-urinary system   
       Chronic renal disease 12 (1.3) 12 (1.3) 
 
a Australian MS Longitudinal Study; b Total comorbidities refer to any comorbidity the participant reported having; c Doctor-diagnosed 
comorbidities refer to any comorbidity the patient reported as diagnosed by a doctor. 








Table 2.  Characteristics of the AMSLSa participants 
Characteristic Study sample (N = 902) 
Age (years), mean (SD) 55.8 (11.4) 
Years since MS diagnosis, mean (SD) 15.4 (9.3) 
Female, n (%) 709 (78.6) 
Currently on Disease Modifying Therapy, n (%) 565 (62.6) 
MS onset-typeb, n (%)  
        Relapse-onset Multiple Sclerosisc 661 (87.4) 
        Progressive-onset Multiple Sclerosisd 95 (12.6) 
Education attainment, n (%)  
       Secondary school or less 298 (33.3) 
      Occupational certificate/Diploma  249 (27.8) 
      University degree and higher 348 (38.9) 
Body mass indexe (kg/m2), n (%)  
      Normal (BMI = 18.5 to 25) 368 (42.2) 
      Overweight (BMI = 25 to 30) 279 (32.0) 
      Obese (BMI = 30 and over) 226 (25.9) 
AQoL-8D’s psychosocial super-dimension scoref, mean (SD) 0.34 (0.19) 
AQoL-8D’s physical super-dimension scoref, mean (SD) 0.58 (0.22) 
Overall AQoL-8D scoref, mean (SD) 0.62 (0.21) 
 
aAustralian MS Longitudinal Study; b Excluded those who ticked “unsure” (n = 103) and those who did not specify their MS onset 
type (n = 43);  c Includes relapsing remitting multiple sclerosis and secondary progressive multiple sclerosis; d Includes primary 
progressive multiple sclerosis and progressive relapsing multiple sclerosis; e Body mass index (BMI) was  calculated by dividing 
self-reported weight (in kilograms) by height2 (in centimetres); fAQoL-8D ranged from 0 (death/worst health state) to 1 (perfect 
health). 





Table 3. Associations between the number of comorbidities and the overall AQoL-8D, AQoL-8D’s psychosocial and physical super-dimensions 







 Number of 




coefficients        
(95% CI) 
Adjusted 
coefficients          
(95% CI)a 
Adjusted coefficients          
(95% CI)a 
Adjusted coefficients          
(95% CI)a 
Total comorbiditiesb 
 0 81 (8.98) 0.73 (0.69, 0.77) Reference 
 1 122 (13.53) 0.71 (0.68, 0.75) -0.02 (-0.07, 0.04) -0.02 (-0.08, 0.04)  -0.02 (-0.08, 0.03)  -0.03 (-0.08, 0.03) 
 2-3 329 (36.47) 0.65 (0.62, 0.67) -0.08 (-0.13, -0.03) -0.09 (-0.14, -0.04) -0.10 (-0.14, -0.05) -0.08 (-0.13, -0.03) 
 4 or more 370 (41.02) 0.55 (0.53, 0.57) -0.18 (-0.23, -0.13) -0.19 (-0.24, -0.14) -0.17 (-0.21, -0.13) -0.16 (-0.21, -0.11) 
 Trend:   p <0.01 p <0.01 p <0.01 p <0.01 
Doctor-diagnosed comorbiditiesc 
 0 122 (13.53) 0.71 (0.67, 0.75) Reference 
 1 175 (19.40) 0.67 (0.64, 0.71) -0.03 (-0.08, 0.01) -0.04 (-0.09, 0.01)  -0.06 (-0.10, -0.01)  -0.03 (-0.07, 0.02) 
 2-3 325 (36.03) 0.64 (0.61, 0.66) -0.07 (-0.12, -0.03) -0.09 (-0.13, -0.04) -0.09 (-0.13, -0.05) -0.07 (-0.11 -0.03) 
 4 or more 280 (31.04) 0.54 (0.51, 0.56) -0.17 (-0.12, -0.13) -0.19 (-0.23, -0.14) -0.16 (-0.20, -0.12) -0.16 (-0.20, -0.12) 
 Trend:   p <0.01 p <0.01 p <0.01 p <0.01 
 
a The values were adjusted for age, sex and education attainment. Negative coefficients indicate worsening of the health-related quality of life (HRQoL). Values in bold font denote statistical significance at 95% confidence interval (CI);  
b Total comorbidities refer to any comorbidity the participant reported having; c Doctor-diagnosed comorbidities refer to any comorbidity the patient reported as diagnosed by a doctor. 
AQoL-8D: Assessment of Quality of Life with eight dimensions. 












































R2 = 18.09% 
R2 = 17.53% 
























Figure 1. The relative contribution (%)a of the 13 comorbidity groupsb based on total comorbiditiesc to 
the overall AQoL-8D (panel A), AQoL-8D’s psychosocial (panel B) and physical (panel C) super-
dimensions.  
a The values were calculated using general dominance analysis and were obtained from the individual standardized weight (out of 100%) of the variance of 
each comorbidity groups over the total variance of the overall AQoL-8D (R2 = 18.09); AQoL-8D’s psychosocial (R2 = 17.53) and physical (R2 = 12.67) 
super-dimensions of the multivariable regression model; b The 13 comorbidity groups were grouped according to the 263 blocks (disease categories) in the 
International Classification of Diseases–10th revision (ICD-10) structure; c Total comorbidities refer to any comorbidity the participant reported having. 
AQoL-8D: Assessment of Quality of Life with eight dimensions.  
R2 = 12.67% 




Table 4. Associations between total comorbiditiesa and overall AQoL-8D people with MS  
 Predicted mean  (95% CI) 
Adjusted coefficients          
 (β, 95% CI)b R-squared (%)
c 
Total variance of the multiple regression 
model (incl. 13 comorbidity groups)    18.09 
 
Predicted AQoL-8D of those without 
comorbidities (Reference) 0.74 (0.69, 0.78)   
Comorbidity groups and individual 
comorbidities    
Mental health disorders   12.35 
      Depression 0.58 (0.53, 0.63) -0.15 (-0.18, -0.13)  
      Anxiety 0.63 (0.57, 0.67) -0.11 (-0.14, -0.08)  
Musculoskeletal disorders   2.28 
      Osteoporosis 0.66 (0.60, 0.72) -0.08 (-0.12, -0.04)  
      Osteoarthritis 0.68 (0.63, 0.74) -0.05 (-0.09, -0.02)  
      Rheumatoid arthritis 0.64 (0.54, 0.74) -0.09 (-0.18, -0.01)  
      Systemic lupus erythematosus 0.57 (0.45, 0.69) -0.16 (-0.27, -0.05)  
Endocrine and Metabolic diseases   0.88 
      High cholesterol 0.73 (0.67, 0.78) -0.01 (-0.04, 0.03)  
      Type 1 diabetes 0.64 (0.50, 0.78) -0.09 (-0.22, 0.03)  
      Type 2 diabetes 0.66 (0.58, 0.74) -0.08 (-0.14, -0.01)  
      Hyperthyroidism 0.61 (0.52, 0.70) -0.12 (-0.20, -0.04)  
      Hypothyroidism 0.69 (0.62, 0.76) -0.04 (-0.09, 0.01)  
Diseases of the nervous system   0.73 
      Epilepsy 0.64 (0.51, 0.76) -0.10 (-0.21, 0.02)  
      Migraine 0.69 (0.63, 0.74) -0.05 (-0.08, -0.01)  
Diseases of the circulatory system   0.44 
      Hypertension 0.73 (0.67, 0.78) -0.01 (-0.04, 0.02)  
      Heart diseases 0.68 (0.60, 0.75) -0.06 (-0.12, -0.01)  
      Myocardial infarction 0.74 (0.63, 0.85) 0.00 (-0.09, 0.11)  
      Stroke 0.70 (0.60, 0.80) -0.03 (-0.12, 0.06)  
      Peripheral vascular disease 0.66 (0.57, 0.76) -0.07 (-0.16, 0.01)  
Diseases of the digestive system   0.35 
      Inflammatory bowel disease 0.63 (0.54, 0.72) -0.10 (-0.18, -0.02)  
      Coeliac disease 0.72 (0.60, 0.84) -0.01 (-0.12, 0.10)  
Eye diseases 0.70 (0.64, 0.76) -0.03 (-0.07, 0.01) 0.31 
Allergies 0.70 (0.65, 0.75) -0.03 (-0.06, -0.01) 0.25 
Other autoimmune diseases 0.66 (0.58, 0.74) -0.07 (-0.14, -0.01) 0.23 
Diseases of the skin   0.18 
       Psoriasis 0.70 (0.63, 0.76) -0.04 (-0.09, 0.01)  
Diseases of the blood   0.04 
       Anaemia 0.72 (0.65, 0.77) -0.02 (-0.06, 0.03)  
Neoplasms   0.02 
       Cancer 0.73 (0.66, 0.78) -0.01 (-0.05, 0.03)  
Diseases of the genito-urinary system   0.02 
       Chronic renal disease 0.67 (0.54, 0.80) -0.07 (-0.19, 0.06)  
 
a Total comorbidities refer to any comorbidity the participant reported having. 
 b Estimated decrease in health-related quality of life that is associated with having the individual comorbidity. The values were adjusted for age, sex and education 
attainment. Bold font indicates statistical significance at 95% confidence interval (CI); c The R-squared (%R2) value is the total variance from the multiple regression 
model and the individual variance contributed by each comorbidity group to the to the total variance as obtained from the general dominance analysis. 
AQoL-8D: Assessment of Quality of Life with eight dimensions. 




Table 5. Associations between total comorbiditiesa and the AQoL-8D’s psychosocial and physical super-dimensions  
Super-dimensions AQoL-8D’s psychosocial super-dimension AQoL-8D’s physical super-dimension 
 Predicted mean  (95% CI) 
Adjusted coefficients 
(β, 95% CI)b 
R-squared 
(%)c 
Predicted mean  
(95% CI) 
Adjusted coefficients 
(β, 95% CI)b 
R-squared 
(%)c 
Total variance of the multiple regression 
model (incl. 13 comorbidity groups)    17.53   12.67 
 
Predicted AQoL-8D of those without 
comorbidities (Reference) 0.45 (0.41, 0.49)   0.68 (0.64, 0.72)   
Comorbidity groups and individual 
comorbidities       
Mental health disorders   14.18   2.50 
      Depression 0.30 (0.26, 0.35) -0.14 (-0.16, -0.11)  0.58 (0.53, 0.63) -0.10 (-0.12, -0.07)  
      Anxiety 0.34 (0.29, 0.39) -0.10 (-0.13, -0.07)  0.62 (0.56, 0.67) -0.06 (-0.09, -0.03)  
Musculoskeletal disorders   0.96   4.93 
      Osteoporosis 0.39 (0.33, 0.44) -0.06 (-0.10, -0.02)  0.62 (0.56, 0.68) -0.06 (-0.10, -0.02)  
      Osteoarthritis 0.42 (0.37, 0.47) -0.03 (-0.06, 0.01)  0.61 (0.56, 0.67) -0.07 (-0.10, -0.04)  
      Rheumatoid arthritis 0.40 (0.31, 0.49) -0.05 (-0.13, 0.03)  0.57 (0.48, 0.67) -0.11 (-0.19, -0.02)  
      Systemic lupus erythematosus 0.35 (0.24, 0.46) -0.09 (-0.19, 0.01)  0.50 (0.38, 0.61) -0.18 (-0.29, -0.07)  
Endocrine and Metabolic diseases   0.68   1.27 
      High cholesterol 0.44 (0.39, 0.49) -0.01 (-0.04, 0.02)  0.67 (0.61, 0.73) -0.01 (-0.04, 0.03)  
      Type 1 diabetes 0.38 (0.25, 0.51) -0.07 (-0.19, 0.05)  0.60 (0.46, 0.73) -0.08 (-0.21, 0.04)  
      Type 2 diabetes 0.37 (0.31, 0.44) -0.07 (-0.13, -0.01)  0.64 (0.57, 0.72) -0.04 (-0.09, 0.03)  
      Hyperthyroidism 0.35 (0.27, 0.43) -0.09 (-0.16, -0.02)  0.57 (0.48, 0.66) -0.11 (-0.19, -0.03)  
      Hypothyroidism 0.41 (0.35, 0.48) -0.03 (-0.08, 0.02)  0.64 (0.57, 0.70) -0.04 (-0.09, 0.01)  
Diseases of the nervous system   0.50   0.35 
      Epilepsy 0.38 (0.27, 0.50) -0.06, (-0.17, 0.04)  0.57 (0.45, 0.69) -0.11 (-0.22, 0.01)  
      Migraine 0.41 (0.36, 0.46) -0.03 (-0.06, -0.01)  0.63 (0.58, 0.69) -0.05 (-0.08, -0.02)  
Table continues 





Diseases of the circulatory system   0.14   1.04 
      Hypertension 0.44 (0.39, 0.49) -0.01 (-0.03, 0.02)  0.68 (0.62, 0.73) 0.00 (-0.03, 0.03)  
      Heart diseases 0.41 (0.34, 0.47) -0.04 (-0.09, 0.01)  0.64 (0.57, 0.71) -0.04 (-0.09, 0.02)  
      Myocardial infarction 0.45 (0.36, 0.56) 0.00 (-0.08, 0.10)  0.67 (0.56, 0.78) -0.01 (-0.11, 0.09)  
      Stroke 0.43 (0.34, 0.52) -0.01 (-0.10, 0.07)  0.62 (0.53, 0.72) -0.05 (-0.14, 0.03)  
      Peripheral vascular disease 0.40 (0.32, 0.49) -0.04 (-0.12, 0.04)  0.62 (0.52, 0.71) -0.06 (-0.14, 0.02)  
Diseases of the digestive system   0.14   0.39 
      Inflammatory bowel disease 0.37 (0.28, 0.45) -0.08 (-0.15, -0.01)  0.57 (0.48, 0.67) -0.10 (-0.18, -0.03)  
      Coeliac disease 0.49 (0.38, 0.60) 0.04 (-0.06, 0.15)  0.67 (0.55, 0.79) -0.01 (-0.11, 0.11)  
Eye diseases 0.41 (0.36, 0.47) -0.03 (-0.07, 0.01) 0.24 0.66 (0.60, 0.72) -0.02 (-0.06, 0.02) 0.77 
Allergies 0.42 (0.37, 0.47) -0.02 (-0.05, 0.01) 0.29 0.64 (0.58, 0.69) -0.04 (-0.07, -0.01) 0.28 
Other autoimmune diseases 0.40 (0.33, 0.47) -0.04 (-0.10, 0.02) 0.12 0.57 (0.49, 0.65) -0.10 (-0.17, -0.04) 0.46 
Diseases of the skin   0.16   0.31 
      Psoriasis 0.42 (0.36, 0.48) -0.03 (-0.07, 0.01)  0.63 (0.56, 0.69) -0.05 (-0.10, -0.01)  
Diseases of the blood   0.03   0.25 
      Anaemia 0.44 (0.38, 0.50) -0.01 (-0.04, 0.03)  0.67 (0.61, 0.73) -0.01 (-0.05, 0.03)  
Neoplasms   0.03   0.10 
      Cancer 0.44 (0.38, 0.49) -0.01 (-0.04, 0.03)  0.68 (0.62, 0.73) -0.01 (-0.04, 0.04)  
Diseases of the genito-urinary system   0.05   0.03 
      Chronic renal disease 0.37 (0.25, 0.49) -0.07 (-0.18, 0.04)  0.65 (0.52, 0.78) -0.03 (-0.15, 0.09)  
 
a Total comorbidities refer to any comorbidity the participant reported having. 
 b Estimated decrease in health-related quality of life that is associated with having the individual comorbidity. The values were adjusted for age, sex and education attainment. Bold font indicates statistical significance at 95% confidence 
interval (CI); c The R-squared (%R2) value is the total variance from the multiple regression model and the individual variance contributed by each comorbidity group to the to the total variance as obtained from the general dominance 
analysis. 
AQoL-8D: Assessment of Quality of Life with eight dimensions. 
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Supplementary Figure 1. The relative contribution (%)a of the 13 comorbidity groupsb based on doctor-
diagnosed comorbiditiesc to the overall AQoL-8D (panel A), AQoL-8D’s psychosocial (panel B) and 
physical (panel C) super-dimensions.  
a The values were calculated using general dominance analysis and were obtained from the individual standardized weight (out of 100%) of the variance of each 
comorbidity groups over the total variance of the overall AQoL-8D (R2 = 14.73); AQoL-8D’s psychosocial (R2 = 13.07) and physical (R2 = 13.48) super-dimensions 
of the multivariable regression model; b The 13 comorbidity groups were grouped to the 263 blocks (disease categories) in the International Classification of Diseases–
10th revision (ICD-10) structure; c Doctor-diagnosed comorbidities refer to any comorbidity the patient reported as diagnosed by a doctor. 
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Supplementary Table 1. Associations between doctor-diagnosed comorbiditiesa and overall AQoL-8D of 
people with MS 
 Predicted mean  (95% CI) 
Adjusted coefficients          
 (β, 95% CI)b R-squared (%)
c 
Total variance of the multiple regression 
model (incl. 13 comorbidity groups)    14.73 
 
Predicted AQoL-8D of those without 
comorbidities (Reference) 0.72 (0.69, 0.76)   
Comorbidity groups and individual 
comorbidities    
Mental health disorders   9.06 
      Depression 0.58 (0.53, 0.62) -0.14 (-0.17, -0.11)  
      Anxiety 0.61 (0.56, 0.66) -0.10 (-0.14, -0.07)  
Diseases of the musculoskeletal system   1.87 
      Osteoporosis 0.65 (0.59, 0,70) -0.07 (-0.12, -0.03)  
      Osteoarthritis 0.67 (0.62, 0.72) -0.05 (-0.09, -0.02)  
      Rheumatoid arthritis 0.65 (0.55, 0.75) -0.07 (-0.16, 0.03)  
      Systemic lupus erythematosus 0.58 (0.46, 0.70) -0.14 (-0.25, -0.02)  
Endocrine and Metabolic diseases   0.80 
      High cholesterol 0.72 (0.67, 0.77) 0.00 (-0.03, 0.03)  
      Type 1 diabetes 0.63 (0.50, 0.76) -0.09 (-0.22, 0.04)  
      Type 2 diabetes 0.65 (0.58, 0.73) 0.06 (-0.13, -0.01)  
      Hyperthyroidism 0.61 (0.52, 0.70) -0.11 (-0.19, -0.03)  
      Hypothyroidism 0.68 (0.62, 0.75) -0.04 (-0.09, 0.02)  
Diseases of the nervous system   0.96 
      Epilepsy 0.65 (0.50, 0.80) -0.07 (-0.21, 0.07)  
      Migraine 0.65 (0.60, 0.70) -0.07 (-0.10, -0.03)  
Diseases of the circulatory system   0.33 
      Hypertension 0.71 (0.67, 0.76) -0.01 (-0.04, 0.03)  
      Heart diseases 0.67 (0.60, 0.73) -0.05 (-0.11, 0.01)  
      Myocardial infarction 0.72 (0.62, 0.83) 0.00 (-0.10, 0.11)  
      Stroke 0.69 (0.59, 0.79) -0.03 (-0.12, 0.06)  
      Peripheral vascular disease 0.65 (0.56, 0.74) -0.07 (-0.15, 0.02)  
Diseases of the digestive system   0.37 
      Inflammatory bowel disease 0.63 (0.54, 0.72) -0.08 (-0.17, -0.01)  
      Coeliac disease 0.67 (0.53, 0.80) -0.05 (-0.18, 0.08)  
Eye diseases 0.68 (0.63, 0.74) -0.04 (-0.08, 0.01) 0.50 
Allergies 0.68 (0.63, 0.73) -0.03 (-0.07, -0.01) 0.35 
Other autoimmune diseases 0.65 (0.57, 0.73) -0.06 (-0.13, 0.01) 0.17 
Diseases of the skin   0.21 
      Psoriasis 0.68 (0.61, 0.75) -0.04 (-0.09, 0.02)  
Diseases of the blood   0.07 
      Anaemia 0.72 (0.66, 0.78) 0.00 (-0.04, 0.04)  
Neoplasms   0.02 
      Cancer 0.72 (0.66, 0.77) 0.00 (-0.04, 0.04)  
Diseases of the genito-urinary system   0.03 
      Chronic renal disease 0.65 (0.53, 0.78) -0.06 (-0.18, 0.06)  
 
a Doctor-diagnosed comorbidities refer to any comorbidity the patient reported as diagnosed by a doctor. 
b Estimated decrease in health-related quality of life that is associated with having the individual comorbidity. The values were adjusted for age, sex and education 
attainment. Bold font indicates statistical significance at 95% confidence interval (CI); c The R-squared (%R2) value is the total variance from the multiple regression 
model and the individual variance contributed by each comorbidity group to the to the total variance as obtained from the general dominance analysis. 
AQoL-8D: Assessment of Quality of Life with eight dimensions. 




Supplementary Table 2. Association between doctor-diagnosed comorbiditiesa and the AQoL-8D’s psychosocial and physical super-dimensions 
Super-dimensions AQoL-8D’s psychosocial super-dimensions AQoL-8D’s physical super-dimensions 
 Predicted mean  (95% CI) 
Adjusted coefficients 
(β, 95% CI)b 
R-squared 
(%)c 
Predicted mean  
(95% CI) 
Adjusted coefficients 
(β, 95% CI)b 
R-squared 
(%)c 
Total variance of the multiple regression 
model (incl. 13 comorbidity groups)    13.07   13.48 
 
Predicted AQoL-8D of those without 
comorbidities (Reference) 0.43 (0.40, 0.47)   0.66 (0.63, 0.70)   
Comorbidity groups and individual 
comorbidities       
Mental health disorders   9.92   2.54 
       Depression 0.31 (0.27, 0.35) -0.12 (-0.15, -0.10)  0.57 (0.52, 0.61) -0.09 (-0.12, -0.06)  
       Anxiety 0.34 (0.29, 0.38) -0.09 (-0.12, -0.06)  0.58 (0.53, 0.63) -0.08 (-0.11, -0.04)  
Musculoskeletal disorders   0.72   4.68 
       Osteoporosis 0.38 (0.33, 0.43) -0.06 (-0.09, -0.02)  0.60 (0.55, 0.66) -0.06 (-0.10, -0.02)  
       Osteoarthritis 0.41 (0.36, 0.45) -0.02 (-0.06, 0.01)  0.67 (0.62, 0.72) -0.05 (-0.09, -0.02)  
       Rheumatoid arthritis 0.41 (0.32, 0.50) -0.02 (-0.11, 0.06)  0.55 (0.45, 0.66) -0.11 (-0.20, -0.01)  
       Systemic lupus erythematosus 0.36 (0.25, 0.47) -0.07 (-0.18, 0.03)  0.49 (0.37, 0.61) -0.17 (-0.28, -0.05)  
Endocrine and Metabolic diseases   0.59   1.23 
       High cholesterol 0.43 (0.39, 0.48) -0.00 (-0.03, 0.03)  0.66 (0.61, 0.71) 0.00 (-0.04, 0.03)  
       Type 1 diabetes 0.37 (0.24, 0.49) -0.06 (-0.19, 0.06)  0.58 (0.45, 0.71) -0.08 (-0.21, 0.05)  
       Type 2 diabetes 0.37 (0.30, 0.44) -0.06 (-0.12, -0.01)  0.63 (0.56, 0.71) -0.03 (-0.09, 0.04)  
       Hyperthyroidism 0.35 (0.27, 0.43) -0.08 (-0.16, -0.01)  0.56 (0.47, 0.65) -0.10 (-0.18, -0.03)  
       Hypothyroidism 0.41 (0.35, 0.47) -0.02 (-0.07, 0.02)  0.62 (0.56, 0.68) -0.04 (-0.09, 0.01)  
Diseases of the nervous system   0.42   1.15 
       Epilepsy 0.39 (0.26, 0.52) -0.04 (-0.17, 0.09)  0.55 (0.41, 0.70) -0.11 (-0.25, 0.03)  
       Migraine 0.40 (0.35, 0.44) -0.04 (-0.07, -0.01)  0.58 (0.53, 0.63) -0.08 (-0.12, -0.05)  
Table continues 





Diseases of the circulatory system   0.08   0.92 
      Hypertension 0.43 (0.39, 0.48) 0.00 (-0.03, 0.03)  0.66 (0.61, 0.71) 0.00 (-0.03, 0.03)  
      Heart diseases 0.40 (0.33, 0.46) -0.04 (-0.09, 0.02)  0.63 (0.56, 0.70) -0.03 (-0.09, 0.03)  
      Myocardial infarction 0.45 (0.35, 0.55) 0.02 (-0.08, 0.11)  0.65 (0.54, 0.76) -0.01 (-0.11, 0.09)  
      Stroke 0.42 (0.33, 0.51) -0.01 (-0.09, 0.07)  0.62 (0.52, 0.71) -0.04 (-0.13, 0.05)  
      Peripheral vascular disease 0.39 (0.31, 0.48) -0.04 (-0.11, 0.04)  0.60 (0.51, 0.69) -0.06 (-0.14, 0.03)  
Diseases of the digestive system   0.13   0.50 
      Inflammatory bowel disease 0.37 (0.28, 0.45) -0.07 (-0.14, 0.01)  0.56 (0.47, 0.65) -0.10 (-0.18, -0.02)  
      Coeliac disease 0.48 (0.35, 0.60) 0.04 (-0.07, 0.16)  0.58 (0.45, 0.72) -0.07 (-0.20, 0.05)  
Eye diseases 0.40 (0.35, 0.45) -0.03 (-0.07, 0.01) 0.40 0.64 (0.59, 0.69) -0.02 (-0.06, 0.02) 0.90 
Allergies 0.41 (0.36, 0.45) -0.02 (-0.05, 0.01) 0.38 0.61 (0.56, 0.66) -0.05 (-0.08, -0.02) 0.36 
Other autoimmune diseases 0.40 (0.33, 0.47) -0.03 (-0.10, 0.03) 0.07 0.55 (0.47, 0.63) -0.11 (-0.18, -0.04) 0.40 
Diseases of the skin   0.23   0.33 
      Psoriasis 0.40 (0.34, 0.46) -0.03 (-0.08, 0.02)  0.61 (0.54, 0.67) -0.05 (-0.11, -0.01)  
Diseases of the blood   0.06   0.36 
      Anaemia 0.44 (0.39, 0.50) 0.01 (-0.03, 0.05)  0.67 (0.61, 0.72) 0.01 (-0.04, 0.05)  
Neoplasms   0.03   0.09 
      Cancer 0.43 (0.38, 0.48) -0.01 (-0.04, 0.03)  0.66 (0.61, 0.72) 0.00 (-0.04, 0.04)  
Diseases of the genito-urinary system   0.04   0.04 
      Chronic renal disease 0.36 (0.25, 0.48) -0.07 (-0.18, 0.04)  0.64 (0.51, 0.76) -0.02 (-0.14, 0.10)  
 
a Doctor-diagnosed comorbidities refer to any comorbidity the patient reported as diagnosed by a doctor. 
b Estimated decrease in health-related quality of life that is associated with having the individual comorbidity. The values were adjusted for age, sex and education attainment. Bold font indicates statistical significance at 95% confidence 
interval (CI); c The R-squared (%R2) value is the total variance from the multiple regression model and the individual variance contributed by each comorbidity group to the to the total variance as obtained from the general dominance 
analysis. 
AQoL-8D: Assessment of Quality of Life with eight dimensions. 
